Inclusion Criteria:

          -  Histologically proven invasive breast cancer.

          -  Primary tumor must be ER-negative (ER in <1% of cells), PR-negative (PR in <1% of
             cells), and HER2-negative (0-1+ by immuno-histochemistry (IHC) or fluorescence in situ
             hybridization (FISH) ratio<2.0 with signal number <6/cell).

          -  Participants must be high-risk, defined as either:

               -  Pathologic stage IIA, IIB, IIIA, IIIB, or IIIC by American Joint Committee on
                  Cancer (AJCC) 8, or

               -  Residual invasive cancer in breast or regional nodes following preoperative
                  chemotherapy.

          -  Patients must have no convincing evidence of recurrent disease based on one of the
             following:

               -  Bone scan and imaging scans of the chest/abdomen/pelvis or

               -  18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan

          -  (≥)1 months since last active therapy (chemotherapy, radiation therapy, or surgery)
             and <36 months since the initiation of treatment for the current cancer, based on the
             period of highest risk for patients with Stages I-III triple-negative breast cancer

          -  Treatment prior to enrollment must be consistent with contemporary National
             Comprehensive Cancer Network (NCCN) guidelines

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          -  Adequate major organ function, defined as:

               -  white blood cell (WBC) count > 3,000/mcl,

               -  hemoglobin > 10.0 gm/dL,

               -  platelets > 100,000/mcL,

               -  total bilirubin within normal limits,

               -  ALT/AST <3 x upper limits of normal (ULN),

               -  serum creatinine < 1.5 x ULN

          -  Serum prolactin level must be < upper limits of normal (ULN);

          -  Participants must have the ability to understand and the willingness to sign and
             provide a written informed consent document;

          -  Participants must have archival tissue available for potential correlative studies
             (e.g., assays for α-lactalbumin expression or tumor infiltrating lymphocytes), but
             tumors will not be required to exhibit overexpression of α-lactalbumin for enrollment.

          -  Participants agrees not to use alternative therapies from the time of informed consent
             through 30 days following the last vaccine injection

        Exclusion Criteria:

          -  Receipt of cytotoxic chemotherapy within 4 weeks of study entry

          -  Radiation therapy within 4 weeks of study entry

          -  Failure to recover from the toxicity of the previous therapy to CTCAE Grade 0-1,
             except for alopecia and grade 2 neuropathy

          -  Need for systemic corticosteroid use (except as physiologic replacement, defined as
             prednisone 10 mg/day or equivalent).

          -  Need for immunosuppression (e.g., for a history of organ transplantation)

          -  Known HIV infection

          -  Active or planned lactation or pregnancy

          -  Patients taking or planning to take oral contraceptives will be excluded, as there is
             some evidence that such agents can induce lactational foci. This includes patients
             using hormone containing IUD's.

          -  Refusal to use effective non-hormonal contraception. Acceptable contraception methods
             include but may not be limited to barrier contraception (diaphragm or condom),
             non-hormonal intrauterine device, vasectomy of male partner

          -  Participants receiving any other investigational agents within the last 4 weeks.

          -  Participants with any known recurrence or metastasis

          -  Participants with a history of another active invasive malignancy within 5 years of
             study entry

          -  History of allergic reactions to α-lactalbumin, human milk (excluding lactose
             intolerance), Zymosan, or other agents used in this study

          -  Participants with uncontrolled intercurrent illness including, but not limited to
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Participants with known hyperprolactinemia

          -  Participants being treated with drugs known to cause hyperprolactinemia

          -  Known allergy to penicillin